Sentinel lymph node mapping with GI cancer

Takashi Aikou, Yuukou Kitagawa, Masaki Kitajima, Yoshikazu Uenosono, Anton J. Bilchik, Steve R. Martinez, Sukamal Saha

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Precise evaluation of lymph node status is one of the most important factors in determining clinical outcome in treating gastro-intestinal (GI) cancer. Sentinel lymph node (SLN) mapping clearly has become highly feasible and accurate in staging GI cancer. The lunchtime symposium focused on the present status of SLN mapping for GI cancer. Dr. Kitigawa proposed a new strategy using sentinel node biopsy for esophageal cancer patients with clinically early stage disease. Dr. Uenosono reported on whether the SLN concept is applicable for gastric cancer through his analysis of more than 180 patients with cT1-2, N0 tumors. The detection rate was 95%, the false negative rate of lymph node metastasis including micro-metastasis was 4%, and accuracy was 99% in gastric cancer patients with cT1N0. Dr. Bilchik recommended the best technique for identifying SLNs in colorectal cancer: a combination of radiotracer and blue dye method, emphasizing that this technique will become increasingly popular because of the SLN concept, with improvement in staging accuracy. He stressed that this novel procedure offers the potential for significant upstaging of GI cancer. Dr. Saha emphasized that SLN mapping for colorectal cancer is highly successful and accurate in predicting the presence or absence of nodal disease with a relatively low incidence of skip metastases. It provided the "right nodes" to the pathologists for detailed analysis for appropriate staging and treatment with adjuvant chemotherapy. Although more evidence from large-scale multicenter clinical trials is required, SLN mapping may be very useful for individualizing multi-modal treatment for esophageal cancer and might be widely acceptable even for GI cancer.

Original languageEnglish
Pages (from-to)269-277
Number of pages9
JournalCancer and Metastasis Reviews
Volume25
Issue number2
DOIs
Publication statusPublished - 2006 Jun

Fingerprint

Intestinal Neoplasms
Esophageal Neoplasms
Neoplasm Metastasis
Stomach Neoplasms
Colorectal Neoplasms
Lymph Nodes
Lunch
Adjuvant Chemotherapy
Multicenter Studies
Sentinel Lymph Node
Coloring Agents
Clinical Trials
Biopsy
Incidence
Therapeutics
Neoplasms

Keywords

  • Lower GI cancer
  • Sentinel lymph nodes
  • Upper GI

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aikou, T., Kitagawa, Y., Kitajima, M., Uenosono, Y., Bilchik, A. J., Martinez, S. R., & Saha, S. (2006). Sentinel lymph node mapping with GI cancer. Cancer and Metastasis Reviews, 25(2), 269-277. https://doi.org/10.1007/s10555-006-8507-3

Sentinel lymph node mapping with GI cancer. / Aikou, Takashi; Kitagawa, Yuukou; Kitajima, Masaki; Uenosono, Yoshikazu; Bilchik, Anton J.; Martinez, Steve R.; Saha, Sukamal.

In: Cancer and Metastasis Reviews, Vol. 25, No. 2, 06.2006, p. 269-277.

Research output: Contribution to journalArticle

Aikou, T, Kitagawa, Y, Kitajima, M, Uenosono, Y, Bilchik, AJ, Martinez, SR & Saha, S 2006, 'Sentinel lymph node mapping with GI cancer', Cancer and Metastasis Reviews, vol. 25, no. 2, pp. 269-277. https://doi.org/10.1007/s10555-006-8507-3
Aikou T, Kitagawa Y, Kitajima M, Uenosono Y, Bilchik AJ, Martinez SR et al. Sentinel lymph node mapping with GI cancer. Cancer and Metastasis Reviews. 2006 Jun;25(2):269-277. https://doi.org/10.1007/s10555-006-8507-3
Aikou, Takashi ; Kitagawa, Yuukou ; Kitajima, Masaki ; Uenosono, Yoshikazu ; Bilchik, Anton J. ; Martinez, Steve R. ; Saha, Sukamal. / Sentinel lymph node mapping with GI cancer. In: Cancer and Metastasis Reviews. 2006 ; Vol. 25, No. 2. pp. 269-277.
@article{3f56e29992b24aec9f4fbe2b41c6821c,
title = "Sentinel lymph node mapping with GI cancer",
abstract = "Precise evaluation of lymph node status is one of the most important factors in determining clinical outcome in treating gastro-intestinal (GI) cancer. Sentinel lymph node (SLN) mapping clearly has become highly feasible and accurate in staging GI cancer. The lunchtime symposium focused on the present status of SLN mapping for GI cancer. Dr. Kitigawa proposed a new strategy using sentinel node biopsy for esophageal cancer patients with clinically early stage disease. Dr. Uenosono reported on whether the SLN concept is applicable for gastric cancer through his analysis of more than 180 patients with cT1-2, N0 tumors. The detection rate was 95{\%}, the false negative rate of lymph node metastasis including micro-metastasis was 4{\%}, and accuracy was 99{\%} in gastric cancer patients with cT1N0. Dr. Bilchik recommended the best technique for identifying SLNs in colorectal cancer: a combination of radiotracer and blue dye method, emphasizing that this technique will become increasingly popular because of the SLN concept, with improvement in staging accuracy. He stressed that this novel procedure offers the potential for significant upstaging of GI cancer. Dr. Saha emphasized that SLN mapping for colorectal cancer is highly successful and accurate in predicting the presence or absence of nodal disease with a relatively low incidence of skip metastases. It provided the {"}right nodes{"} to the pathologists for detailed analysis for appropriate staging and treatment with adjuvant chemotherapy. Although more evidence from large-scale multicenter clinical trials is required, SLN mapping may be very useful for individualizing multi-modal treatment for esophageal cancer and might be widely acceptable even for GI cancer.",
keywords = "Lower GI cancer, Sentinel lymph nodes, Upper GI",
author = "Takashi Aikou and Yuukou Kitagawa and Masaki Kitajima and Yoshikazu Uenosono and Bilchik, {Anton J.} and Martinez, {Steve R.} and Sukamal Saha",
year = "2006",
month = "6",
doi = "10.1007/s10555-006-8507-3",
language = "English",
volume = "25",
pages = "269--277",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Sentinel lymph node mapping with GI cancer

AU - Aikou, Takashi

AU - Kitagawa, Yuukou

AU - Kitajima, Masaki

AU - Uenosono, Yoshikazu

AU - Bilchik, Anton J.

AU - Martinez, Steve R.

AU - Saha, Sukamal

PY - 2006/6

Y1 - 2006/6

N2 - Precise evaluation of lymph node status is one of the most important factors in determining clinical outcome in treating gastro-intestinal (GI) cancer. Sentinel lymph node (SLN) mapping clearly has become highly feasible and accurate in staging GI cancer. The lunchtime symposium focused on the present status of SLN mapping for GI cancer. Dr. Kitigawa proposed a new strategy using sentinel node biopsy for esophageal cancer patients with clinically early stage disease. Dr. Uenosono reported on whether the SLN concept is applicable for gastric cancer through his analysis of more than 180 patients with cT1-2, N0 tumors. The detection rate was 95%, the false negative rate of lymph node metastasis including micro-metastasis was 4%, and accuracy was 99% in gastric cancer patients with cT1N0. Dr. Bilchik recommended the best technique for identifying SLNs in colorectal cancer: a combination of radiotracer and blue dye method, emphasizing that this technique will become increasingly popular because of the SLN concept, with improvement in staging accuracy. He stressed that this novel procedure offers the potential for significant upstaging of GI cancer. Dr. Saha emphasized that SLN mapping for colorectal cancer is highly successful and accurate in predicting the presence or absence of nodal disease with a relatively low incidence of skip metastases. It provided the "right nodes" to the pathologists for detailed analysis for appropriate staging and treatment with adjuvant chemotherapy. Although more evidence from large-scale multicenter clinical trials is required, SLN mapping may be very useful for individualizing multi-modal treatment for esophageal cancer and might be widely acceptable even for GI cancer.

AB - Precise evaluation of lymph node status is one of the most important factors in determining clinical outcome in treating gastro-intestinal (GI) cancer. Sentinel lymph node (SLN) mapping clearly has become highly feasible and accurate in staging GI cancer. The lunchtime symposium focused on the present status of SLN mapping for GI cancer. Dr. Kitigawa proposed a new strategy using sentinel node biopsy for esophageal cancer patients with clinically early stage disease. Dr. Uenosono reported on whether the SLN concept is applicable for gastric cancer through his analysis of more than 180 patients with cT1-2, N0 tumors. The detection rate was 95%, the false negative rate of lymph node metastasis including micro-metastasis was 4%, and accuracy was 99% in gastric cancer patients with cT1N0. Dr. Bilchik recommended the best technique for identifying SLNs in colorectal cancer: a combination of radiotracer and blue dye method, emphasizing that this technique will become increasingly popular because of the SLN concept, with improvement in staging accuracy. He stressed that this novel procedure offers the potential for significant upstaging of GI cancer. Dr. Saha emphasized that SLN mapping for colorectal cancer is highly successful and accurate in predicting the presence or absence of nodal disease with a relatively low incidence of skip metastases. It provided the "right nodes" to the pathologists for detailed analysis for appropriate staging and treatment with adjuvant chemotherapy. Although more evidence from large-scale multicenter clinical trials is required, SLN mapping may be very useful for individualizing multi-modal treatment for esophageal cancer and might be widely acceptable even for GI cancer.

KW - Lower GI cancer

KW - Sentinel lymph nodes

KW - Upper GI

UR - http://www.scopus.com/inward/record.url?scp=33745079957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745079957&partnerID=8YFLogxK

U2 - 10.1007/s10555-006-8507-3

DO - 10.1007/s10555-006-8507-3

M3 - Article

C2 - 16770539

AN - SCOPUS:33745079957

VL - 25

SP - 269

EP - 277

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 2

ER -